ACTR-19. REPORT ON THE COMBINATION OF AXITINIB AND TUMOR TREATING FIELDS (TTFIELDS) IN THREE PATIENTS WITH RECURRENT GLIOBLASTOMA

OBJECTIVE: Tumor Treating Fields (TTFields) significantly improved survival of newly diagnosed glioblastoma (ndGBM) patients in the EF-14 trial. Axitinib is an orally available tyrosine kinase inhibitor which is approved for the treatment of metastatic renal cell carcinoma. It has a high affinity an...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Schulz, Ellina, Kessler, Almuth F, Weiland, Judith, Linsenmann, Thomas, Ernestus, Ralf-Ingo, Hagemann, Carsten, Löhr, Mario
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Adult Clinical Trials - Non-Immunologic
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847705/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.062
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires